-
Mashup Score: 1
PURPOSE We previously reported that enzalutamide improved overall survival when added to standard of care in metastatic, hormone-sensitive prostate cancer. Here, we report its effects on aspects of health-related quality of life (HRQL). METHODS HRQL was assessed with the European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire and QLM-PR25 at weeks 0, 4, 12,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
benefit of docetaxel (CHAARTED, STAMPEDE), abiraterone (LATITUDE, STAMPEDE), apalutamide (TITAN), and enzalutamide (ARCHES, ENZAMET), management of metastatic hormone-sensitive prostate cancer (mHSPC), Ian Davis.
Source: www.urotoday.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Commentary on this paper just published on @urotoday "Beyond the abstract" #ENZAMET #TITAN @ANZUPtrials @ChrisSweens1 https://t.co/DicRjoX5DV https://t.co/mH4YgITmrK
-
-
Mashup Score: 2Please wait whilst we redirect you - 3 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2021 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V.
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#ENZAMET shows 60% increase in OS / incr 3 yr OS from 83% to 92% at 33 months follow-up for pts with metach low vol mHSPC https://t.co/5YnBdl8jiu Should control arm for SBRT oligomet HSPC trials be? @ANZUPtrials @Uromigos @APCCC_Lugano @DanaFarber_GU @PCF_Science @EUplatinum
-
-
Mashup Score: 0Please wait whilst we redirect you - 3 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2021 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V.
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
... continued 4) is #3 / SBRT "reasonable" with incr 3y OS from 83% to 92% for metach low vol with enzalutimde in #ENZAMET and supported by apalutamide #TITAN @ANZUPtrials @APCCC_Lugano @Prof_IanD @Uromigos @scserendipity1 @DanaFarber_GU @neerajaiims https://t.co/5YnBdl8jiu https://t.co/iXsX36uqi7
-
-
Mashup Score: 0Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer - 3 year(s) ago
This systematic review and network meta-analysis compares the results of randomized clinical trials that evaluated the use of medications used in the treatment of metastatic castration-resistant prostate cancer.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Interesting meta-analysis of mHSPC trials in @JAMAOnc but I think unreasonably hard on enzalutamide: only #ENZAMET had OS as primary endpoint, and was the only one with an active control and allowed concurrent chemo; ARCHES reported OS data were immature. https://t.co/0hwp7OLOJV
-
-
Mashup Score: 0Dr. Petrylak on the Role of Docetaxel in mHSPC - 3 year(s) ago
Daniel P. Petrylak, MD, discusses the role of docetaxel based on the results of the ENZAMET trial in metastatic hormone-sensitive prostate cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@DanielPetrylak of @YaleCancer, spotlights the role of docetaxel based on the results of the #ENZAMET trial in metastatic hormone-sensitive prostate cancer #pcsm https://t.co/iZiOrIAu2j
-
-
Mashup Score: 0Dr. Petrylak on the Role of Docetaxel in mHSPC - 3 year(s) ago
Daniel P. Petrylak, MD, discusses the role of docetaxel based on the results of the ENZAMET trial in metastatic hormone-sensitive prostate cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@DanielPetrylak of @YaleCancer, on the role of docetaxel based on the results of the #ENZAMET trial in metastatic hormone-sensitive prostate cancer #pcsm https://t.co/7vqjTopVSD
-
-
Mashup Score: 0
ENZAMET Trial, ACTA Trial of the Year prostate cancer ENZAMET Trial, ENZAMET trial for men with metastatic prostate cancer
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
The #ENZAMET clinical trial for #ProstateCancer awarded 2020 ACTA Trial of the Year! Congratulations to everyone involved! #ReadNow details on UroToday > https://t.co/6OHUMpC2Qz @ChrisSweens1 @Prof_IanD @ACTA_org @ANZUPtrials @Sydney_Uni https://t.co/ICdR06jeoa
-
-
Mashup Score: 1
ESMO 2019 health-related quality of life outcomes from men in the ENZAmet study, enzalutamide plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer (mHSPC)
Source: www.urotoday.comCategories: UrologyTweet-
Health-related QoL of Enzalutamide with standard first-line therapy for mHSPC #ENZAMET discussion by @MartinStockler @Sydney_Uni. #ESMO19 Medical oncologist's perspective from @jberchuck @DanaFarber on UroToday > https://t.co/4caBve5b7X @myESMO https://t.co/hfYjXH1n2u
-
Treatment w ENZA was associated w worse fatigue, physical & cognitive functions #ProstateCancer #PROs Comprehensive & elegant study Congrats to #ENZAMET team @MartinStockler @Prof_IanD @ChrisSweens1 @hagsie @nickymitchell @DrRobZielinski @AnthonyMJoshua https://t.co/SdvU93tyzA https://t.co/K0N0VmPlDz